Twist Bioscience Corporation Operating Lease, Expense
Twist Bioscience Corporation (TWST) reported Operating Lease, Expense of $3.80 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2024-08-02
- Twist Bioscience Corporation operating lease, expense for the quarter ending 2024-06-30 was $3.80M, a 2.56% decline year-over-year.
- Twist Bioscience Corporation operating lease, expense for the quarter ending 2024-03-31 was $3.90M, a 4.88% decline year-over-year.
- Twist Bioscience Corporation operating lease, expense for the quarter ending 2023-12-31 was $4.00M, a 2.44% decline year-over-year.
- Twist Bioscience Corporation operating lease, expense for the quarter ending 2023-09-30 was $4.00M, a 2.44% decline year-over-year.
- Twist Bioscience Corporation operating lease, expense for fiscal 2023 was $16.20M, a 3.85% increase from fiscal 2022.
- Twist Bioscience Corporation operating lease, expense for fiscal 2022 was $15.60M, a 64.21% increase from fiscal 2021.
- Twist Bioscience Corporation operating lease, expense for fiscal 2021 was $9.50M, a 20.25% increase from fiscal 2020.
- Twist Bioscience Corporation operating lease, expense for fiscal 2020 was $7.90M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $3.80M 10-Q · filed 2024-08-02 | $7.70M derived: sum of 2 quarters · filed 2024-08-02 | $11.80M 10-Q · filed 2024-08-02 | $15.70M derived: sum of 4 quarters · filed 2024-08-02 |
| 2024-03-31 | $3.90M 10-Q · filed 2024-05-02 | $7.90M 10-Q · filed 2024-05-02 | $11.90M derived: sum of 3 quarters · filed 2024-05-02 | $15.80M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-12-31 | $4.00M 10-Q · filed 2024-02-02 | $8.00M derived: sum of 2 quarters · filed 2024-02-02 | $11.90M derived: sum of 3 quarters · filed 2024-08-02 | $16.00M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-09-30 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $7.90M derived: sum of 2 quarters · filed 2024-08-02 | $12.00M derived: sum of 3 quarters · filed 2024-08-02 | $16.20M 10-K · filed 2023-11-21 |
| 2023-06-30 | $3.90M 10-Q · filed 2024-08-02 | $8.00M derived: sum of 2 quarters · filed 2024-08-02 | $12.20M 10-Q · filed 2024-08-02 | $16.20M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-03-31 | $4.10M 10-Q · filed 2024-05-02 | $8.20M 10-Q · filed 2024-05-02 | $12.30M derived: sum of 3 quarters · filed 2024-05-02 | $16.40M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $4.10M 10-Q · filed 2024-02-02 | $8.20M derived: sum of 2 quarters · filed 2024-02-02 | $12.30M derived: sum of 3 quarters · filed 2024-02-02 | $16.20M derived: sum of 4 quarters · filed 2024-02-02 |
| 2022-09-30 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $8.20M derived: sum of 2 quarters · filed 2023-11-21 | $12.10M derived: sum of 3 quarters · filed 2023-11-21 | $15.60M 10-K · filed 2023-11-21 |
| 2022-06-30 | $4.10M 10-Q · filed 2023-08-07 | $8.00M derived: sum of 2 quarters · filed 2023-08-07 | $11.50M 10-Q · filed 2023-08-07 | $14.50M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $3.90M 10-Q · filed 2023-05-08 | $7.40M 10-Q · filed 2023-05-08 | $10.40M derived: sum of 3 quarters · filed 2023-06-05 | $13.10M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-12-31 | $3.50M 10-Q · filed 2023-02-07 | $6.50M derived: sum of 2 quarters · filed 2023-06-05 | $9.20M derived: sum of 3 quarters · filed 2023-06-05 | $11.10M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-09-30 | $3.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $5.70M derived: sum of 2 quarters · filed 2023-06-05 | $7.60M derived: sum of 3 quarters · filed 2023-06-05 | $9.50M 10-K/A · filed 2023-06-05 |
| 2021-06-30 | $2.70M 10-Q · filed 2021-08-09 | $4.60M derived: sum of 2 quarters · filed 2021-08-09 | $6.50M 10-Q · filed 2021-08-09 | $8.50M derived: sum of 4 quarters · filed 2022-02-09 |
| 2021-03-31 | $1.90M 10-Q · filed 2021-05-07 | $3.80M 10-Q · filed 2021-05-07 | $5.80M derived: sum of 3 quarters · filed 2022-02-09 | $7.70M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-12-31 | $1.90M 10-Q · filed 2022-02-09 | $3.90M derived: sum of 2 quarters · filed 2022-02-09 | $5.80M derived: sum of 3 quarters · filed 2022-02-09 | $7.70M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-09-30 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | $3.90M derived: sum of 2 quarters · filed 2021-11-23 | $5.80M derived: sum of 3 quarters · filed 2021-11-23 | $7.90M 10-K · filed 2021-11-23 |
| 2020-06-30 | $1.90M 10-Q · filed 2020-08-12 | $3.80M derived: sum of 2 quarters · filed 2020-08-12 | $5.90M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $1.90M 10-Q · filed 2020-05-13 | $3.90M 10-Q · filed 2020-05-13 | ||
| 2019-12-31 | $2.00M 10-Q · filed 2021-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |